Document is current

Article History

Received: 2 March 2023

Accepted: 16 March 2023

First Online: 26 March 2023

Declarations

:

: Animal studies described herein were carried out in accordance with the Guide for the Care and Use of Laboratory Animals of Tel Aviv University (TAU; Tel Aviv, Israel). All protocols were approved by the TAU Institutional Animal Care and Use Committee (IACUC).

: Not applicable.

: The studies described in this manuscript were sponsored and conducted by NeoTX therapeutics Ltd., which develops tumor-targeted superantigens for tumor treatment. NeoTX Therapeutics Ltd. has a sublicensing agreement with Active Biotech. M.A., M.S., E.S., E.E., and S.L. serve as paid employees of NeoTX Therapeutics Ltd, are listed as inventors on NeoTX Therapeutics Ltd. patents and patent applications related to TTSs, and hold stock options in NeoTX Therapeutics Ltd. M.T. is a paid employee of Active Biotech and a shareholder. G.H. hold shares in Active Biotech AB and is listed as inventor of Active Biotech AB patents related to TTSs. R.K., G.H., and A.F. serve as consultants to NeoTX Therapeutics Ltd.